A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, retinal diseases and other diseases of the eye
News Highlights
Aerie Pharmaceuticals Submits Marketing Authorisation Application for ... Aerie Pharmaceuticals Receives European Commission Approval for Rhokii... Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, ...STOCK Quote
NASDAQ: AERI
$22.50USD
Dec 13, 4:00 PM ET
VOLUME
1,016,618
DAY LOW/HIGH
$22.10/$23.17
52 - WEEK LOW/HIGH
$17.15/$50.10
